江西祥宇医药有限公司

Why it is here

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — abuse of a dominant market position (上海市市场监管局上海市市场监督管理局 · 沪市监反垄处〔2023〕3220190101510号 · 市场监管总局发布江西祥宇医药有限公司滥用市场支配地位案行政处罚决定书), from 20 March 2024.

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — Abuse of a dominant market position.

Details

Company

江西祥宇医药有限公司

Authority

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn)

Decision

Abuse of a dominant market position

Grounds and details, as published

上海市市场监管局上海市市场监督管理局 · 沪市监反垄处〔2023〕3220190101510号 · 市场监管总局发布江西祥宇医药有限公司滥用市场支配地位案行政处罚决定书

From

20 March 2024

Until

—

Status

End date not published

Source

https://www.samr.gov.cn/fldys/tzgg/xzcf/art/2024/art_f8c05b72707b4720b76bb09902a9f854.html

Licence

Public antitrust decisions published by the State Administration for Market Regulation of China (samr.gov.cn/fldys)